TGA Makes Illegal Peptides a 2026 Compliance Priority Amid Safety Concerns
10 Jun 2026
On Wednesday, the medicines regulator formally added unapproved peptide products to its priority enforcement areas. These products are often promoted online for anti-ageing and performance enhancement purposes.
The TGA said the move reflects a “scaling up of regulatory attention” due to rising importation, expanded online marketing, and growing safety concerns linked to these substances.
The regulator has previously issued warnings about compounded or prescribed peptide products that do not meet regulatory requirements. It says the latest decision builds on ongoing action against unapproved therapeutic goods.
The popularity of injectable peptides has grown rapidly across Australia. A June newsGP poll found that 65% of GPs had seen an increase in patients asking about these products.
Department of Health, Disability and Ageing Deputy Secretary and TGA head Professor Anthony Lawler said the decision was a “risk-based response” to a changing market.
He warned that Australians should be cautious about purchasing unapproved peptide products online, particularly from overseas or social media platforms, saying there is no guarantee of safety, quality, or sterility.
RACGP President Dr Michael Wright supported the TGA’s action, describing the situation as unsafe and unclear for both patients and GPs.
He said unregulated products circulating on the black and grey market may not meet Australian safety standards and could contain unknown substances.
Dr Wright also said patients face real risks when using these products without medical supervision, and that evidence for their effectiveness is limited or absent.
Earlier enforcement efforts have already targeted illegal supply chains. An eight-month operation involving the TGA, Australian Border Force, and Victoria Police resulted in the seizure of about $2 million worth of peptides, performance-enhancing drugs, and illicit steroids.
The TGA confirmed that future non-compliance actions may include fines, seizures, import restrictions, and civil or criminal penalties.
Its Compliance Principles for 2026–27 outline priority areas for monitoring and enforcement. Current focus areas include peptides, medicinal cannabis, vaping goods, weight-loss medicines, sunscreens, and unapproved diagnostic kits, among others.
GPs are encouraged to report suspected illegal or non-compliant therapeutic goods through the TGA website.
TGA Makes Illegal Peptides a 2026 Compliance Priority Amid Safety Concerns
Source: newsGP